Drug Target Review’s Post

Have you signed up for our upcoming webinar with Bio-Rad Laboratories? Now's the time! Key takeaways: ✅ Discover the rise of HSV-1 Vectors: learn why these vectors are poised to transform gene therapy. ✅ Explore the unique attributes of HSV-1 vectors, ideal for neurological applications and beyond. ✅ Learn how customisation of HSV-1 vectors can unlock a multitude of advantages, from expanding capacity to enabling sustained expression. ✅ Engage with our experts as they share their outlook on the future of cell and gene therapy.

💡 This article might be a refresher about the leading gene therapy vector (#AAV), but it also proved an invaluable learning resource, deepening my understanding of the rapidly evolving gene therapy landscape. Advancements in #vectorengineering and manufacturing technologies are pivotal in examining the transformative potential of viral vector-based gene therapies. One of the primary goals of gene therapies is to benefit every patient, irrespective of their disease stage and progression. How do we actually make that happen? 🔥 There is no definitive answer, but one thing is conclusive—the dialogue around how we achieve the goal through good science is ablaze. From enhancing #capsiddesign and implementing #optimization procedures to broader concepts such as integrating #CRISPR for precise genetic modifications, the pursuit of advancement in this field is vital.  I'd like to hear your take on the challenges we face and how the latest innovations (and recent approvals) can reshape the landscape of treatment for a multitude of diseases. https://lnkd.in/gbfFXnTu #GeneTherapy #Innovation #DINAMIQS #Siegfried

Cell and gene therapies are transforming the landscape of disease treatment — but inefficiencies in infrastructure represent a significant bottleneck to therapeutic development. That’s exactly why ElevateBio was founded — to accelerate access to the cutting-edge technologies and expertise that will change the future of medicine. Learn how their purpose-built platform speeds up science: ⚡ Increases sample throughput by 10X ⚡ Improves scientist efficiency and impact ⚡ Facilitates earlier identification of potential bottlenecks See how ElevateBio is using Benchling to accelerate cell and gene therapy R&D by tackling infrastructure inefficiencies: https://lnkd.in/egmmDbUe #BuiltOnBenchling

At Infirmacea, we're pioneering a fat-directed #DNAtherapy - a safe and cost-effective approach to #genetherapy. By injecting DNA into subcutaneous fat, we transform this tissue into a “health engine” that can boost disease resistance. Since fat is both abundant and easily accessible for injection, it presents an ideal target for gene therapy, making our method highly efficient and practical. One of the key challenges in this field has been efficiently transfecting fat cells, terminally differentiated ones, without using viral vectors. We’ve overcome this with our revolutionary technology, #gBoost, a cell-selective gene expression enhancer, enabling effective non-viral delivery and opening new possibilities for advanced gene therapies.

Contract development and research organizations such as ElevateBio face a unique challenge: they must remain flexible enough to engage with various partners and programs while also maintaining efficiency and cost-effectiveness. However, achieving efficiency becomes challenging when standardization is not readily achievable. It's great to see how they are effectively balancing these demands. Benchling, by supporting flexibility through no-code configuration, enables them to systematize how they manage their processes while accommodating the inherent variations in their business.

Detecting Exposure Risk from Gene Therapy Viral Vectors.

We are proud to be recognised in the BioIndustry Association (BIA) Cell and Gene Therapy report, which outlines the UK’s pivotal role in advancing life-changing cell and gene therapy research to deliver transformative outcomes for patients living with debilitating or life-shortening conditions. To date, there has been a lack of innovation in treatment options for chronic kidney disease, despite a patient population of over 840 million people worldwide. Purespring’s novel  gene therapy platform, which delivers a disease-modifying gene directly to the podocyte, has the potential to make a real difference to the lives of patients around the world. For more information on the UK’s thriving #CellandGeneTherapy ecosystem, read the full report here: https://lnkd.in/dZJ_4H4Y #GeneTherapy #CellandGeneUK #Biotech #KidneyDiseases

In a recent interview, Johannes Stanta, Global Director of Molecular and Cell Biology at Celerion, discusses "Detecting Exposure Risk from Gene Therapy Viral Vectors." Dr. Stanta and his team have been making groundbreaking strides in gene therapy. They've developed a new, streamlined approach for shedding assays specifically tailored for adeno-associated virus (AAV) vectors. AAV vectors are currently the most popular in gene therapies, and this innovative method ensures more accurate detection of exposure risks. "I hope that we spark a new bioanalytical revolution in the space of PCR where everyone starts doing it this way." – Johannes Stanta, Celerion Check out the interview now to explore how these advancements are shaping the future of gene therapy: https://lnkd.in/emvh--HF #GeneTherapy #Innovation #Bioanalytical

How are advancements in analytics and manufacturing processes improving the production of #AAV and #adenovirus for gene therapies? 🔎📊📈 We are excited to be featured in GEN article, "Analytics Key to AV and AAV Manufacturing", by Angelo DePalma, highlighting our efforts in developing more effective and scalable adenovirus production solutions. The article showcases our #iCELLis adherent cell platform, which exemplifies our dedication to ensuring high-density cell cultures and high-quality gene therapy solutions. 👩🏼🔬🧪🔬 Check out the article to learn more and let us know what you think! Article link available in comments. 🔗 #3PBIOVIAN #GEN #AAV #Biotech #GeneTherapy #ViralVectors

What does the future of gene therapy look like? 🔮 📅 Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent disease. 🚧 💬 In a conversation with Spur Therapeutics’s CEO Michael Parini, we talk about the future of this technology and the biotech’s Gaucher disease gene therapy poised to enter phase 3 next year. 🧬 🎧 Tune in to the latest episode of the Beyond Biotech Podcast to learn more! 👇 https://lnkd.in/d_nXpGQb #BeyondBiotechPodcast #genetherapy #futureofmedicine #biotechinnovation #Gaucherdisease #healthcarerevolution #therapeuticadvancements